Is RIGL or RLYB more undervalued in 2026?

CirclFi compares Rigel Pharmaceuticals, Inc. (RIGL) and Rallybio Corporation (RLYB) using 13 institutional-grade valuation models. RIGL has a Quality of Company score of 9.1/10 while RLYB scores 5.4/10.

Which is a better buy — RIGL or RLYB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RIGL and RLYB valuations compare?

RIGL at $30.49 and RLYB at $14.46 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RIGL vs RLYB Valuation Comparison 2026 — Intrinsic Value Analysis

RIGL

Pharmaceutical Preparations

Rigel Pharmaceuticals, Inc.

Quality

9.1

out of 10

Value Trap

SAFE

Price

$30.49

Last close

Models

12/13

Active

RLYB

Pharmaceutical Preparations

Rallybio Corporation

Quality

5.4

out of 10

Value Trap

SAFE

Price

$14.46

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	RIGL Fair Value	RIGL Upside	RLYB Fair Value	RLYB Upside
Bayesian DCF	Intrinsic	$21.04	-31.0%	$8.09	-44.1%
Earnings Power Value	Intrinsic	$50.82	+66.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$16.84	-44.8%	$17.56	+21.4%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RIGL vs RLYB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RIGL vs RLYB — Which Stock Is More Undervalued?

RIGL scores higher with a 9.1/10 quality rating vs RLYB's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Rigel Pharmaceuticals, Inc. (RIGL) and Rallybio Corporation (RLYB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RIGL currently trades at $30.49 with a QOC of 9.1/10, while RLYB trades at $14.46 with a QOC of 5.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).